Established in the year 1991 under the dynamic leadership of Mr. K Subba Rao, Chairman, VEF, the Institution has grown leaps and bounds. The first batch of students passed out of the college on 8th November 1995 which happens to be the red letter day when the premier Dental Council of India gave recognition to the Institution.
“Vignan Educational Foundation” which is a registered trust established in the Garden city of Bengaluru in the year 1991

ADMISSION – NOTICE (2013-2014)
(Recognized Certified Programme by RGUHS, Karnataka)

“Vignan Educational Foundation” which is a registered trust established in the Garden city of Bengaluru in the year 1991 has today reached excellence in various fields of education in India and abroad.
Bangalore Institute of Dental Sciences and Hospital and Postgraduate Research Centre, Bengaluru
Vignan Institute of Nursing, Bengaluru
1. Oral Medicine and Radiology
2. Oral & Maxillofacial Surgery
3. Orthodontics & Dentofacial Orthopaedics
4. Periodontia
5. Prosthodontia
6. Conservative Dentistry and Endodontics
7. Oral Pathology and Microbiology.
8. Public Health Dentistry.
9. Preventing and Pediatric Dentistry

Monthly Archives: March 2017

When somebody has carpal tunnel syndrome.

What Causes It? Anything pressing in the median nerve can cause CTS. The tendons moving through the carpal tunnel may become swollen from performing the same movement again and again, like typing on a pc or playing video gaming or a musical instrument for long periods of time. It’s more prevalent in gymnasts, those who do a large amount of handstands particularly, and in individuals who play racquet sports, like tennis. Broken or dislocated wrist bones or even sprains that cause swelling around the carpal tunnel might trigger CTS, too. Medical issues that increase someone’s threat of getting CTS consist of arthritis, thyroid complications, and diabetes. Continue reading

000 poultry within a 500-metre radius of the farm.

Based on the World Wellness Organisation since 2003 there were 258 cases of individual disease of the H5N1 strain, which includes killed 153 people. The majority of those deaths had been in Asia and practically all occurred because of handing diseased poultry or birds. The World Wellness Business fears the H5N1 strain may mutate right into a virus which can be transmitted from individual to human being. South Korean authorities believe there is usually little risk to human beings and suspect the foundation virus was probably from migratory birds, tourist visitors, or the smuggling of livestock and produce from overseas.. Continue reading

In the article side effects.

In the article, C & EN editor Ivan Amato focuses on synonyms in the genetic code – very short word-like sequences or codons translate in exactly the same amino acids in the construction of a protein. These so-called synonymous codons, the three-dimensional shape of a protein architecture influence of critical importance for health and disease side effects . ‘It can be compared to the kind the same hand in a reaffirmation thumbs up conformation or in a form with the middle finger, which gives entirely a different mood swing,’Amato said.

Are less likely have difficulty accessing mental health careThe AP / Monterey County Herald on Sunday examined how many low-income immigrants and their families have problems with access to mental health treatment because of ‘language barrier and a deep cultural divide. ‘The National Latino and Asian American study, conducted in December 2003 with funding from the National Institute of Mental Health, found that Latino and Asian immigrants less a lower rate of mental health problems than native U.S. Citizens, but sought treatment for their problems often. According to a report in 2001 by the Office of the Surgeon General, racial and ethnic minorities are often the mental health mental health treatment due to an English English and look for a lack of health insurance. The report found that 37 percent of Latinos lack health insurance , and that fewer than one in 20 with mental health problems sought treatment of mental specialists. In addition, the report found that Asian – Pacific Islanders are less likely venerable mental health treatment or to discuss mental health problems with friends or relatives than were whites. The report recommended more research, the geographic distribution of mental health providers and the availability of treatments for patients individually to address ‘significant differences in knowledge, use, and quality of mental health care for racial and ethnic minorities. ‘AP AP / County Herald, many immigrants also fail the mental health treatment because of the ‘time-honored preconceptions about mental health problems ‘ to look for. ‘Courtesy of you, the entire Kaiser Daily Health Policy view Report, search the archives, or sign up for email delivery at Kaiser Daily Health Policy Report strongly supported imperial network a free service of The Henry J. Published. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved. Continue reading

According to small research conducted by experts at the University of Montreal.

None of the scholarly study individuals were signed up for a smoking cessation system or were trying to give up. Experts asked each participant to smoke cigarettes one cigarette 30 to 40 a few minutes before going through an fMRI, or brain scan. These were asked to see photos both related and unrelated to smoking. After undergoing the mind scans they seen the photos another period and reported on a level from zero to 100 if the photos triggered cigarette cravings. The experts examined 13 of the feminine individuals twice to assess how their response transformed at a different stage within their menstrual cycle. The mind scans showed that through the follicular stage, cigarette imagery activated five regions of the mind that your researchers say are associated with higher-level cravings. However through the luteal stage – – after a female ovulates and before her period – – only 1 area of the mind was activated by pictures of cigarettes and cigarette smoking. Continue reading

And as it happens that there is also different takes on chronic pain.

Chronic discomfort such as fibromyalgia can have a debilitating effect on people's lives, impairing their capability to participate in everyday activities, including work and fun, and compromising personal romantic relationships. Characterized by chronic widespread muscle discomfort and tenderness, fibromyalgia is normally accompanied by morning hours stiffness, poor fatigue and sleep.. Campaign to educate women and men about fibromyalgia Women and men have opposing sights on many topics, and as it happens that there is also different takes on chronic pain. Continue reading

Alnylam third quarter 2012 revenues decrease to $16 cialis 20.

Alnylam third quarter 2012 revenues decrease to $16 cialis 20 .8 million Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, today reported its consolidated economic results for the 3rd quarter 2012, and company highlights. ‘The highlights of the quarter include the positive results we reported inside our clinical programs and our continuing execution on our 'Alnylam 5×15' product strategy. Specifically, we reported positive data from a Phase I study and continued enrollment in our Phase II research of ALN-TTR02. We also showed encouraging pre-clinical data in applications using our GalNAc conjugate delivery system that allows subcutaneous administration of RNAi therapeutics; these include ALN-TTRsc for the treating ALN-AT3 and ATTR for the treatment of hemophilia. Finally, we were pleased to report complete results from a Phase IIb trial of ALN-RSV01 for the treating respiratory syncytial virus an infection in lung transplant sufferers,’ said John Maraganore, Ph.D., CEO of Alnylam. ‘Continued execution on our 'Alnylam 5×15' product strategy remains our primary focus, and we aim to complete our Phase II trial for ALN-TTR02 in mid-2013 and initiate our Stage III trial by the end of 2013. In addition, we expect to file an IND for ALN-TTRsc by end of this year and an IND for ALN-AT3 by mid-2013. With our recent accomplishments inside our pipeline efforts, we have strengthened confidence that we can progress RNAi therapeutics toward genetically defined targets for illnesses that now have limited treatment options for individuals and their caregivers.’ ‘As well as the substantial progress in our 'Alnylam 5×15' efforts, we have advanced our business development efforts through fresh collaborations with Genzyme also, Monsanto, and Ascletis,’ stated Barry Greene, President and Chief Operating Officer of Alnylam. ‘Notably, we produced a strategic alliance with Genzyme to progress ALN-TTR in Japan and the broader Asian-Pacific area. ATTR is an endemic disease in Japan, and we believe this fresh alliance promises to provide our ALN-TTR program to these individuals sooner and to reach the forex market faster. We are also worked up about the alliance we shaped with Monsanto, a leader in neuro-scientific agriculture. This collaboration facilitates wide usage of our intellectual home and technology in agricultural applications and enables extra value creation for Alnylam outside of our focus on human therapeutics. Finally, we shaped a strategic collaboration with Ascletis to develop ALN-VSP for the treatment of liver cancers in China, while we retain privileges in the rest of the global world.’ Cash, Cash Equivalents and Total Marketable Securities At September 30, 2012, Alnylam had cash, cash equivalents and total marketable securities of $295.8 million, as compared to $ December 31 8 million, 2011. Net Loss The net reduction according to accounting concepts generally approved in the U.S. for the 3rd one fourth of 2012 was $19.5 million, or $0.38 per share on both a simple and diluted basis , when compared with a net lack of $13.2 million, or $0.31 per share on both a basic and diluted basis , for the same period in the last year. Revenues Revenues had been $16.8 million for the third quarter of 2012, when compared with $20.8 million for the same period last year. Revenues for the 3rd quarter of 2012 included $9.3 million of collaboration revenues linked to the company's alliance with Roche , $5.5 million of revenues from the company's alliance with Takeda Pharmaceuticals Firm Limited, and $2.0 million of expense reimbursement, amortization, and/or license fee revenues from Cubist Pharmaceuticals, Inc. Looking ahead, Alnylam expects revenues to diminish due to the completion of amortization of Roche/Arrowhead deferred income during the third quarter of 2012. Study and Development Expenses Research and development expenses had been $22.1 million in the third quarter of 2012, including $2.3 million of noncash stock-based compensation, when compared with $24.3 million in the third quarter of 2011, including $2.8 million of noncash stock-based compensation. The decrease in R&D expenses in the third quarter of 2012 in comparison with the prior year period was due primarily to lower scientific trial and manufacturing expenses linked to the company's ALN-RSV and ALN-VSP programs, partially offset by additional expenditures linked to the advancement of the organization's ALN-TTR system. Alnylam expects R&D expenses shall remain consistent for the remainder of 2012. General and Administrative Expenses General and administrative expenses had been $12.8 million in the 3rd quarter of 2012, including $1.1 million of noncash stock-based compensation, as compared to $9.0 million in the 3rd quarter of 2011, which included $1.5 million of noncash stock-based compensation. The increase in G&A expenditures for the 3rd quarter of 2012 when compared with the last season period was due primarily to a rise in consulting and professional solutions linked to business and legal activities. Alnylam expects G&A expenses shall remain consistent for the remainder of 2012. Regulus Therapeutics Equity in loss of jv was $1.6 million and $0.5 million for the third quarter of 2012 and 2011, respectively, linked to our share of the net losses incurred by Regulus. Interest Income Curiosity income was $0.3 million for the third quarter of 2012 and 2011. 2012 Financial Guidance Alnylam now expects that its cash, cash equivalents and total marketable securities balance will be greater than $280 million at December 31, 2012, in comparison with its previous guidance of year-end cash of greater than $250 million. The organization's boost to its year-end money guidance is because of upfront obligations from new alliances with Monsanto and Genzyme. ‘Alnylam continues to keep a solid monetary profile, ending the 3rd quarter with approximately $296 million in money, which excludes the upfront payment of $22.5 million from our recent alliance with Genzyme which was received in the fourth quarter,’ said Michael Mason, Vice President, Finance and Treasurer of Alnylam. ‘Due to our successful business development activities, we have now believe we will end 2012 with greater than $280 million in cash, that may continue to provide us with a strong balance sheet as we advance our RNAi therapeutics through medical trials and toward the market.’ Third One fourth 2012 and Latest Significant Corporate Highlights Crucial ‘Alnylam 5×15’ System Highlights Reported Positive Clinical Data with ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin-Mediated for the treating TTR-Mediated Amyloidosis . Outcomes from a Stage I study of ALN-TTR02 were presented at Boston University School of Medicine, displaying that administration of ALN-TTR02 results in robust knockdown of serum TTR proteins degrees of up to 94 percent; the entire results were extremely significant . Knockdown of TTR, the disease-causing protein in ATTR, was discovered to be rapid, dose dependent, durable, and particular after a single dose just. ALN-TTR02 was found to be generally secure and well tolerated in this Phase I normal human volunteer study, consistent with Alnylam's broader clinical knowledge with lipid nanoparticle -formulated siRNA which include over 100 sufferers or subjects, over 325 total dosages administered, and a length of treatment exceeding two years. In addition, Alnylam reported data at the 8th Oligonucleotide Therapeutics Society conference held October 28-31 in Boston, displaying that the consequences of ALN-TTR02 were RNAi mediated, providing yet further molecular evidence for efficacy of RNAi therapeutics in guy. Specifically, using Alnylam's circulating exosome RNA detection technique, RNAi-mediated cleavage of the TTR mRNA transcript was demonstrated by a 5'RACE analysis of serum samples from subjects receiving ALN-TTR02. Continued Enrollment in ALN-TTR02 Stage II Trial. Alnylam continues to enroll patients in its Phase II trial with ALN-TTR02 for the treating ATTR. This is an open-label, multi-center, multi-dose, dose-escalation trial designed to enroll 20 ATTR individuals approximately. Subjects are getting enrolled into cohorts of raising doses and so are receiving ALN-TTR02 once every four weeks for two cycles. The principal objectives of the study are to judge the protection and tolerability of multiple dosages of ALN-TTR02 also to measure scientific activity based on serial measurement of circulating serum TTR levels. Alnylam expects to comprehensive this trial in mid-2013. Presented Pre-medical Data with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of ATTR. Data provided at the XX International Roundtable on Nucleosides, Nucleotides and Nucleic Acids held August 5-9, 2012 in Montreal, Canada, showed potent, dose-dependent, and long lasting knockdown of serum TTR with Alnylam's GalNAc-conjugate strategy in its ALN-TTRsc pre-clinical program. In non-human primates, ALN-TTRsc was administered in a loading regimen of once a day for five days, accompanied by a maintenance regimen of once weekly for four weeks resulting in an approximately 80 percent reduction of TTR at doses as low as 2.5 mg/kg. Furthermore, in single dosage and multi-dose pre-clinical basic safety research in rodents and nonhuman primates, ALN-TTRsc was found to be generally safe and well tolerated with a ‘no adverse impact level’ greater than or add up to 300 mg/kg and a therapeutic index exceeding 100 fold, like the absence of any kind of injection site elevations or reactions in pro-inflammatory markers. Extra data were presented at the OTS meeting also. Alnylam expects to file an investigational new drug program for ALN-TTRsc by year's end. Designated ALN-AT3, an RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia, as Development Candidate; Presented New Pre-clinical Data at Multiple Meetings. Data had been offered at multiple scientific meetings including the World Federation of Hemophilia World Congress kept July 8-12, 2012 in Paris, the IRT conference, and the OTS meeting. In aggregate, research findings show that subcutaneous administration of ALN-AT3, which employs Alnylam's GalNAc-siRNA conjugate approach, results in potent, dose-dependent, and durable silencing of AT in pre-clinical models and that In reduction can normalize thrombin generation in an animal model of hemophilia, establishing proof of concept because of this program. Specifically, ALN-AT3 demonstrated powerful activity in both mice and nonhuman primates, with an ED50 for AT plasma protein knockdown of approximately 1 mg/kg after an individual subcutaneous dose; nadir knockdown levels of AT were attained by about day 15, with effects lasting over 22 days. In multi-dose rodent research, once weekly subcutaneous dosage administration of ALN-AT3 resulted in an ED50 and ED80 for AT plasma protein knockdown of 0.25 mg/kg and 0.75 mg/kg, respectively. Further, in research performed in mouse models of hemophilia, ALN-AT3 was found to accomplish dose-dependent knockdown of endogenous AT also to significantly increase and normalize thrombin era. In aggregate, these fresh data support a once-a-week or twice-a-month subcutaneous dosing paradigm. Alnylam expects to document an IND program for ALN-AT3 in 2013. Advanced Additional ‘Alnylam 5×15’ Programs. Alnylam continues to progress its extra 'Alnylam 5×15' programs, including: ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia; ALN-HPN, an RNAi therapeutic targeting the hepcidin pathway for the treating refractory anemia; and ALN-TMP, an RNAi therapeutic targeting TMPRSS6 for the treating hemoglobinopathies, amongst additional pre-clinical programs. The company aims to advance these and other applications into further development stages with partnerships it intends to form. In addition, Alnylam provided data at the OTS conference demonstrating era of a GalNAc-siRNA conjugate in its ALN-PCS system. Specifically, the brand new ALN-PCSsc drug applicant demonstrated powerful knockdown of the PCSK9 target gene with an ED50 <0.3 mg/kg after a single subcutaneous dose. Related StoriesAnalyzing potential TB vaccineArsenic exposure during pregnancy might increase risk of infections, respiratory symptoms in childrenDengue-infected patients with few or no symptoms transmit virus to mosquitoes Key Partnered Program Highlights Presented Complete Results From Stage IIb Clinical Trial of ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus Disease in Lung Transplant Individuals. The Phase IIb study was a double-blind, placebo-controlled, randomized global study of ALN-RSV01 with a primary endpoint of the incidence of fresh or progressive bronchiolitis obliterans syndrome at 180 days after RSV illness. At the European Respiratory Society Annual Congress, held September 1-5, 2012 in Vienna, Alnylam presented new outcomes from essential secondary endpoints and certain post-hoc data analyses. Particularly, ALN-RSV01 treatment resulted in a statistically significant decrease in time 90 BOS as compared with placebos end. Business and Organizational Highlights Formed Strategic Alliance with Genzyme to Advance ALN-TTR in Japan and Broader Asian Marketplace. Alnylam and Genzyme, a Sanofi company, entered into an exclusive alliance to develop and commercialize ALN-TTR in Japan and the broader Asian-Pacific area. Genzyme will leverage its tested regulatory and commercial capabilities in japan and broader Asian market to progress the ALN-TTR program, which include ALN-TTR02 and ALN-TTRsc. Alnylam shall maintain programs to develop and commercialize ALN-TTR in the United States, Europe, and rest of the world. Under the terms of the contract, Genzyme has made an upfront cash payment of $22.5 million to Alnylam. Furthermore, Alnylam is eligible to receive certain success-based development milestone payments totaling up to $50 million. Furthermore, Genzyme can make tiered royalty payments to Alnylam that are expected to yield a highly effective price in the mid-teenagers to mid-twenties on product sales of ALN-TTR in the territories covered by Genzyme. Formed Strategic Alliance with Monsanto to Progress RNAi in the Field of Agriculture. Alnylam and Monsanto Firm formed a strategic alliance to advance biological technologies in neuro-scientific agriculture. Under the terms of the contract, Monsanto receives worldwide, special rights to make use of Alnylam's system technology and IP in the field of agriculture. The deal contains $29.2 million in upfront obligations from Monsanto to Alnylam. Alnylam is also eligible to receive milestone obligations and extra funding for collaborative analysis efforts. In addition, Alnylam is permitted receive royalty obligations on items utilizing Alnylam IP. Moreover, Monsanto is Alnylam's strategic partner in agriculture for a ten-year period. Attained Milestone from GlaxoSmithKline from VaxiRNA Collaboration. Alnylam earned a advancement milestone payment from GSK in the quantity of $3. Alnylam's VaxiRNA platform uses RNAi technology for the enhanced manufacturing of vaccine products. Produced Strategic Collaboration with Ascletis to Develop ALN-VSP. Ascletis and Alnylam Pharmaceuticals Co., Ltd. , a kept US-China joint venture pharmaceutical company privately, shaped a strategic collaboration for the advancement of ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of liver cancers including hepatocellular carcinoma , a significant area of unmet need in China. Alnylam will retain all rights in all of those other world, and is eligible to receive milestones and royalties based on product sales. Entered into Agreement with Major Pharmaceutical Organization to judge Alnylam Biotherapeutics Technology. Alnylam reported today that it has formed a new agreement with a pharmaceutical partner to evaluate Alnylam's Biotherapeutics technology, which aims to make use of RNAi technology to improve the manufacturing procedures for biologics. Regulus Created Strategic Alliances and Completed Initial Public Offering . Regulus and AstraZeneca entered into a strategic alliance aimed at advancing microRNA therapeutics for three microRNA targets focused on cardiovascular and metabolic diseases and oncology, all of which are in pre-clinical development. AstraZeneca produced a payment of $28 million, which include an equity investment and an upfront payment to Regulus. Furthermore, Regulus is permitted receive commercial and clinical milestone payments from AstraZeneca, as well as royalties. Biogen and Regulus Idec created a collaboration to explore microRNA biomarkers for multiple sclerosis, which included an equity expense in Regulus in addition to upfront and milestone obligations. In 2012 October, Regulus finished an IPO, raising $50.9 million in gross proceeds of an over-allotment exercise by the underwriters. Regulus' common share started trading on the NASDAQ Global Marketplace on October 4, 2012 under the symbol ‘RGLS.’ Due to the IPO, Alnylam's possession position in Regulus now stands at 17 percent. Alnylam Expects Trial with Tekmira to begin with November 14. With respect to its ongoing litigation in the Massachusetts Business Court with Tekmira Pharmaceuticals Company, Alnylam expects a jury trial to commence on November 14, 2012. The company's financial assistance for 2012 excludes payments, if any, that could be made in connection with the resolution of the ongoing litigation. Continue reading

Beneficial Alzheimers therapies.

Esme Moniz-Make of the Institute of Rehabilitation, Hull York Medical College, UK, will define psychosocial intervention in dementia treatment and review a few of the interventions that are recognized to help. She shall discuss recent research conducted in the united kingdom. Mary Mittleman, D.P.H. Of the brand new York University, Langone INFIRMARY, USA will discuss her encounter Translating the NYU Caregiver Intervention from Study to Practice Configurations. The day’s second plenary program will address this issue of Can We Prevent Alzheimer’s. Planned topics/presenters are: – The Avoidance Working Band of ADI. Continue reading

Only those pieces of silica is less than 50 nanometers in size completely prevent icing read.

Cao writes in Langmuir that while each compound containing silica bits of 10 or less microns deflected water, only those pieces of silica is less than 50 nanometers in size completely prevent icing. The minute area of the smaller fragments means they make minimal contact with the water read . Instead, the water is mainly the air pockets between the particles and touches falls away completely covered. Though not all superhydrophobic coatings follow the Pitt recipe, the researchers conclude that every type will be another particle – scale for repelling ice than for repelling water have.

ASRM guidelines call for the transfer of one or two embryos in patients younger than 35 years in order to reduce the risk of multiple births. Data from 2007, published online by the Society for Assisted Reproductive Technology, show an ASRM affiliate that Kamrava transfer 4.1 embryos on average in patients younger than 35 years reported. The group decided to expel Kamrava late last month, Sean Tipton, a spokesman ASRM. ‘We have a disciplinary committee, gathers information gathers information, we give people the opportunity to explain himself, and then we will take action if the committee deems it necessary, ‘Tipton said. He added that only states have revoked the power, medical licenses, but some insurance companies cover treatments only if they are performed by ASRM members (Rubin, USA Today – ` courtesy of you , the total daily Women display ‘s Health Policy Report search the archives, or sign up for email delivery here emphatically. Daily Women’s Health Policy Report is a free service of the National Partnership for Women & Families by the Advisory Board Company is published. Continue reading

An FDA inspection found rodent feces.

An FDA inspection found rodent feces, rodent hair, rodent nesting material, and building defects with which rodents and other pests, food storage and other areas that might be to the to the infestation.

– Fill your contact lens case with fresh solution from the bottle each time the lenses. Under no circumstances old solution or ‘top off’old solution in the storage case. Continue reading

Population HIV / AIDS Awareness Day.

LaTanya Hines, President of the Association of Black Women Physicians.. The total U.S. Population HIV / AIDS Awareness Day, Los AngelesOffice of AIDS Programs and Policy:What: A Rally / Human Billboard is for National Black HIV / AIDS Awareness Day take on 7 February.The goal of the Rally / Human Billboard and free HIV testing is to draw attention to the devastating impact of HIV / AIDS on the African-American community.

Los Angeles County – African-Americans make up about 9 percent of the population but accounted for 20 percent of all AIDS cases. Despite their relatively small numbers, African Americans have the highest incidence of any racial or ethnic group in Los Angeles County. Continue reading